Trial Profile
Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2023 Planned End Date changed from 3 Jun 2023 to 30 Jun 2025.
- 12 Jun 2023 Planned primary completion date changed from 3 Jun 2023 to 30 Jun 2025.